Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...

German biotech BioNTech today announced positive results from the primary analysis of a Phase II cohort evaluating German ...

Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an ...

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will ...

BioNTech SE (NASDAQ:BNTX) is one of the best high growth healthcare stocks to buy now. On March 11, BMO Capital cut the price ...

High-rolling investors have positioned themselves bullish on BioNTech (NASDAQ:BNTX), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...

In trading on Tuesday, shares of BioNTech SE (Symbol: BNTX) crossed below their 200 day moving average of $104.70, changing hands as low as $97.22 per share. BioNTech SE shares are currently trading ...

BioNTech (NASDAQ:BNTX) is preparing to release its quarterly earnings on Tuesday, 2026-03-10. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from ...

Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans for an independent company to be established and led by BioNTech ...